Zotarolimus | ABT-578 | CAS#221877-54-9 | immunosuppressant

MedKoo Cat#: 326662 | Name: Zotarolimus

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zotarolimus, also known as ABT-578 and A-179578, is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. Medtronic are using zotarolimus as the anti-proliferative agent in the polymer coating of their Endeavor and Resolute products.

Chemical Structure

Zotarolimus

CAS#221877-54-9

Theoretical Analysis

MedKoo Cat#: 326662

Name: Zotarolimus

CAS#: 221877-54-9

Chemical Formula: C52H79N5O12

Exact Mass: 965.5725

Molecular Weight: 966.23

Elemental Analysis: C, 64.64; H, 8.24; N, 7.25; O, 19.87

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

A-179578; A 179578; A179578; ABT578; ABT-578; ABT 578; Endeavor; Zotarolimus; Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-.

IUPAC/Chemical Name

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-3-{(1R)-2-[(1S,3R,4S)-3-methoxy-4-(1H-tetrazol-1-yl)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone

InChi Key

CGTADGCBEXYWNE-JUKNQOCSSA-N

InChi Code

InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

SMILES Code

O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)CC[C@@](O2)([H])C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C([C@H](OC)[C@H](O)/C(C)=C/[C@H]3C)=O)=O)=O)O[C@H]([C@H](C)C[C@H]4C[C@@H](OC)[C@@H](N5N=NN=C5)CC4)CC3=O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 966.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ullah W, Sandhyavenu H, Zaidi SR, Alonso M, Khan MA, Ullah I, Yasmin F, Polam AR, Zahid S, Kumar A, Steyerberg EW, Murtaza M, Alraiesm C, Rade JJ. Safety and Efficacy of Different Stent Strategies in Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Adv. 2025 Feb 18;4(3):101600. doi: 10.1016/j.jacadv.2025.101600. Epub ahead of print. PMID: 39970740. 2: Undale VR, Lembhe SK, Satone SD, Hase P. A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction. Int J Angiol. 2024 Oct 21;34(1):23-32. doi: 10.1055/s-0044-1791556. PMID: 39944137; PMCID: PMC11813614. 3: Zornitzki L, Smits PC, Love MP, Stone GW, Kandzari DE, Redfors B, Ozan MO, Konigstein M. Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials. J Am Heart Assoc. 2024 Nov 19;13(22):e036210. doi: 10.1161/JAHA.124.036210. Epub 2024 Nov 15. PMID: 39547969; PMCID: PMC11681401. 4: Erlinge D, Andersson J, Fröbert O, Törnerud M, Hamid M, Kellerth T, Grimfjärd P, Winnberg O, Jurga J, Wagner H, Zwackman S, Adielsson M, Alström P, Masoe E, Ulvenstam A, Millgård J, Böhm F, Held C, Renlund H, Oldgren J, Smits PC, Elek C, Abizaid A, James S. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single- blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024 Nov 2;404(10464):1750-1759. doi: 10.1016/S0140-6736(24)02227-X. Epub 2024 Oct 28. PMID: 39481425. 5: Ploumen EH, Wolcherink MJO, Buiten RA, Pinxterhuis TH, Doggen CJM, Schotborgh CE, Danse PW, Scholte M, van Houwelingen KG, Zocca P, Pouwels XGLV, von Birgelen C. Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years. Pharmacoecon Open. 2025 Jan;9(1):137-145. doi: 10.1007/s41669-024-00539-x. Epub 2024 Oct 29. PMID: 39472363; PMCID: PMC11718029. 6: Chahine A, Morsi RZ, Thind S, Kass-Hout O, Becske T, Khaldi A, Karar L, Baskaran A, Carrión-Penagos J, Desai H, Kothari SA, Rana R, Verhagen Metman O, Zakaria J, Shah AP, Paul JD, Nathan S, Siegler JE, Mendelson SJ, Mansour A, Hurley MC, Prabhakaran S, Gupta R, Kass-Hout T. Use of Onyx Frontier™ for intracranial stenting in stroke patients: A multicenter retrospective study. Interv Neuroradiol. 2024 Oct 21:15910199241286922. doi: 10.1177/15910199241286922. Epub ahead of print. PMID: 39429004; PMCID: PMC11559875. 7: Lee SJ, Cho J, Shin J, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, You SC, Kim BK. Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation. J Am Heart Assoc. 2024 Oct;13(19):e034862. doi: 10.1161/JAHA.124.034862. Epub 2024 Sep 30. PMID: 39344653; PMCID: PMC11681487. 8: Wang Z, Chen G, Li H, Liu J, Yang Y, Zhao C, Li Y, Shi J, Chen H, Chen G. Zotarolimus alleviates post-trabeculectomy fibrosis via dual functions of anti- inflammation and regulating AMPK/mTOR axis. Int Immunopharmacol. 2024 Dec 5;142(Pt B):113176. doi: 10.1016/j.intimp.2024.113176. Epub 2024 Sep 19. PMID: 39303539. 9: Ravi S, Bhatti IA, Nunna RS, Khalid S, Tekle WG, Tanweer O, Burkhardt JK, Jabbour PM, Tjoumakaris SI, Herial NA, Siddiqui AH, Grandhi R, Qureshi AI, Siddiq F, Hassan AE. 1-Year outcomes of Resolute Onyx Zotarolimus-Eluting Stent for symptomatic intracranial atherosclerotic disease: A multicenter propensity score-matched comparison with stenting versus aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. Interv Neuroradiol. 2024 Sep 12:15910199241278033. doi: 10.1177/15910199241278033. Epub ahead of print. PMID: 39267355; PMCID: PMC11559795. 10: Kang J, Abdul Ghapar AK, Selvaraj K, Hur SH, Tam CC, Jang Y, Chae IH, Kandzari DE, Kirtane AJ, Latib A, Kedhi E, Lung TH, You SJ, Windecker S, Stone GW, Kim HS. One-Month Dual Antiplatelet Therapy in High Bleeding Risk Asian Patients Undergoing Percutaneous Coronary Intervention　- Onyx ONE Clear 2-Year Results. Circ Rep. 2024 Jul 6;6(8):333-340. doi: 10.1253/circrep.CR-24-0037. PMID: 39132335; PMCID: PMC11309775. 11: Price MJ, Boutis L, Kirtane AJ, Chetcuti S, Poliačiková P, Dens J, Attubato M, Wang Y, Hu P, Spriggs D, Krasnow J, Chatzizisis Y, Aminian A, Caputo R, Shah A, Dauler M, Ibrahim S, Lung TH, Mehran R. Three-Year Outcomes After Bifurcation Stenting With Zotarolimus-Eluting Stents: Final Results From the RESOLUTE ONYX Postapproval Study. J Soc Cardiovasc Angiogr Interv. 2023 Aug 5;2(6Part A):101116. doi: 10.1016/j.jscai.2023.101116. PMID: 39129891; PMCID: PMC11308709. 12: Erlinge D, Andersson J, Fröbert O, Törnerud M, Böhm F, Held C, Elek C, Sirhan M, Oldgren J, James S. Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent. Am Heart J. 2024 Nov;277:1-10. doi: 10.1016/j.ahj.2024.07.016. Epub 2024 Aug 2. PMID: 39098754. 13: Hashimoto S, Motozawa Y, Mano T. Selection Criteria in the Era of Perfect Competition for Drug-Eluting Stents in Association With Operator Volumes: An Operator-Volume Analysis of the Selection DES Study. Cardiol Res. 2024 Jun;15(3):189-197. doi: 10.14740/cr1651. Epub 2024 Jun 25. PMID: 38994230; PMCID: PMC11236343. 14: Zarogoulidis P, Huang H, Freitag L. Drug-eluting stents from cardiology to pneumonology. Future Cardiol. 2024;20(7-8):335-337. doi: 10.1080/14796678.2024.2368346. Epub 2024 Jul 2. PMID: 38953508; PMCID: PMC11457726. 15: Basit J, Ahmed M, Shafiq A, Zaheer Z, Nashwan AJ, Ahmed A, Hamza M, Naseer U, Ali S, Gupta N, Sattar Y, Kawsara A, Daggubati R, Alraies MC. Temporal Trends in the Outcomes of Percutaneous Coronary Intervention With Zotarolimus Eluting Stents Versus Everolimus Eluting Stents: A Meta-Analysis of Randomized Controlled Trials. Clin Cardiol. 2024 Jun;47(6):e24306. doi: 10.1002/clc.24306. PMID: 38888152; PMCID: PMC11184471. 16: Zhang F, Wang W, Zhu Y, Mao Y, Wang T, Gao P. Coronary stent implantation links to the occurrence of eosinophilia and interstitial pneumonia: a case report and systematic review. BMC Pulm Med. 2024 Jun 17;24(1):281. doi: 10.1186/s12890-024-03101-x. PMID: 38886703; PMCID: PMC11184702. 17: Kawai K, Sato Y, Cornelissen A, Kolodgie FD, Cheng Q, Kawakami R, Konishi T, Perkins LEL, Virmani R, Finn AV. Comparison of thrombogenicity in different types of drug-eluting stents during transition from DAPT to SAPT. Catheter Cardiovasc Interv. 2024 Jul;104(1):10-20. doi: 10.1002/ccd.31083. Epub 2024 May 20. PMID: 38769726. 18: van Vliet D, Ploumen EH, Pinxterhuis TH, Buiten RA, Aminian A, Schotborgh CE, Danse PW, Roguin A, Anthonio RL, Benit E, Zocca P, Doggen CJM, von Birgelen C. Final 5-year report of BIONYX comparing the thin-composite wire-strut zotarolimus-eluting stent versus ultrathin-strut sirolimus-eluting stent. Catheter Cardiovasc Interv. 2024 Jul;104(1):1-9. doi: 10.1002/ccd.31067. Epub 2024 May 7. PMID: 38713843. 19: Kim HW, Kim SS, Kim HK, Ki YJ, Park KH, Choi DH. Seven-year follow-up of endovascular treatment of iatrogenic brachioradial artery injury complicating percutaneous coronary intervention: a case report. Nagoya J Med Sci. 2024 Feb;86(1):155-159. doi: 10.18999/nagjms.86.1.155. PMID: 38505728; PMCID: PMC10945224. 20: Drozda JP Jr, Ssemaganda H, Frankenberger EA, Brandt E, Robbins S, Khairnar N, Cha A, Resnic FS. Testing a Cloud-Based Model for Active Surveillance of Medical Devices with Analyses of Coronary Stent Safety Using the Data Extraction and Longitudinal Trend Analysis (DELTA) System. Med Devices (Auckl). 2024 Feb 27;17:97-105. doi: 10.2147/MDER.S445160. PMID: 38434149; PMCID: PMC10908332.